Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) CFO David Jin bought 7,605 shares of Fortress Biotech stock in a transaction dated Thursday, November 19th. The stock was acquired at an average cost of $1.87 per share, with a total value of $14,221.35. Following the completion of the acquisition, the chief financial officer directly owned 1,700,366 shares of the company's stock, valued at approximately $3,179,684.42. The trade was a 0.45% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
David Jin also recently made the following trade(s):
- On Wednesday, November 18th, David Jin purchased 25,000 shares of Fortress Biotech stock. The stock was bought at an average price of $1.91 per share, for a total transaction of $47,750.00.
- On Tuesday, November 17th, David Jin acquired 15,000 shares of Fortress Biotech stock. The shares were bought at an average cost of $1.72 per share, with a total value of $25,800.00.
Fortress Biotech Stock Performance
Shares of Fortress Biotech stock traded down $0.11 during trading hours on Thursday, hitting $1.78. 194,841 shares of the company were exchanged, compared to its average volume of 586,980. The business has a 50-day moving average of $2.08 and a 200-day moving average of $2.70. Fortress Biotech, Inc. has a 1 year low of $1.64 and a 1 year high of $4.53. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $60.16 million, a price-to-earnings ratio of 0.78 and a beta of 1.27.
Fortress Biotech (NASDAQ:FBIO - Get Free Report) last released its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. The company had revenue of $19.16 million for the quarter, compared to analysts' expectations of $21.57 million.
Recent Fortress Biotech Headlines
Here are a few of the latest headlines about FBIO:
- Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
- Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article
Analysts Set New Price Targets
A number of analysts have commented on the company. Wall Street Zen downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of Fortress Biotech from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, October 23rd. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $17.00.
View Our Latest Stock Analysis on FBIO
Institutional Investors Weigh In On Fortress Biotech
Hedge funds and other institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new position in Fortress Biotech during the second quarter worth about $47,000. Renaissance Technologies LLC grew its holdings in Fortress Biotech by 22.8% in the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company's stock valued at $278,000 after buying an additional 18,490 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Fortress Biotech in the 3rd quarter valued at about $462,000. Hedge funds and other institutional investors own 96.51% of the company's stock.
Fortress Biotech Company Profile
(
Get Free Report)
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company's activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.